AOD-9604 – 5MG

What Is AOD-9604? Benefits & Overview

AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone (hGH 176–191) and one of the most studied metabolic peptides available in Canada. Unlike full-length HGH, AOD-9604 retains the lipolytic and anti-lipogenic properties of the HGH C-terminal region without affecting IGF-1 levels or causing insulin resistance — making it a targeted option for fat metabolism and body composition protocols.

It holds FDA Generally Recognized as Safe (GRAS) status for use in food products, reflecting an established safety profile in preclinical and early clinical studies.

AOD-9604 Benefits & Uses

• Lipolysis stimulation and free fatty acid release in adipose tissue models
• Lipogenesis inhibition research
• Visceral and subcutaneous fat reduction studies
• Obesity and body composition research without IGF-1 involvement
• Cartilage and bone repair as a secondary research area

How AOD-9604 Works

AOD-9604 mimics the lipolytic domain of native hGH by activating beta-3 adrenergic receptors in adipocytes, stimulating intracellular cAMP production and activating hormone-sensitive lipase (HSL) to break down stored triglycerides. Crucially, it does not bind the GH receptor in a way that activates JAK2/STAT5 signalling or IGF-1 production — isolating the fat-mobilisation effect from the growth-promoting cascade.

AOD-9604 5mg Vial Specifications

• Sequence: Tyr-hGH(177–191) fragment
• Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
• Molecular Weight: 1,815.1 Da
• Purity: ≥98% (third-party HPLC verified)
• Form: Lyophilized powder
• Vial Size: 5 mg
• Storage: −20 °C (long-term); 4 °C (short-term)
• Reconstitution: Bacteriostatic water

AOD-9604 Canada FAQs

Does AOD-9604 raise IGF-1 levels?

No. AOD-9604 is specifically designed to lack the IGF-1-stimulating activity of full hGH. It targets adipose tissue lipolysis via beta-adrenergic and cAMP pathways without activating the GH receptor’s JAK2/STAT5 anabolic cascade.

Is AOD-9604 available in Canada?

Yes. Reviv Peptides supplies AOD-9604 across Canada use only.

What is the difference between AOD-9604 and HGH Fragment 176-191?

AOD-9604 (Tyr-hGH₁₇₇₋₁₉₁) includes an additional tyrosine residue added to the N-terminus of the standard 176–191 fragment for enhanced stability. The peptide sequence otherwise targets the same lipolytic domain of human growth hormone.

Reconstitution & Dosing Guide

How to Reconstitute

Add 3.0 mL of bacteriostatic water to the vial. Inject the water slowly down the inside wall of the vial — do not inject directly onto the powder. Gently swirl until fully dissolved; do not shake. This yields approximately 1.67 mg/mL. Store the reconstituted vial at 4 °C and use within 28 days.

Low Starting Dose

• Dose per injection: 300 mcg — 18 units (0.18 mL) on a U-100 insulin syringe
• Frequency: Once daily, subcutaneous injection (morning, fasted)
• Cycle length: 8–12 weeks

Start at the lowest effective dose and adjust based on individual response. Consult a qualified healthcare professional before use.